158 related articles for article (PubMed ID: 37583815)
1. Discovery of
Tian Y; Qin S; Zhang F; Luo J; He X; Sun Y; Yang T
ACS Med Chem Lett; 2023 Aug; 14(8):1113-1121. PubMed ID: 37583815
[TBL] [Abstract][Full Text] [Related]
2.
Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
[TBL] [Abstract][Full Text] [Related]
3. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
4. Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2.
Xu P; Shen P; Wang H; Qin L; Ren J; Sun Q; Ge R; Bian J; Zhong Y; Li Z; Wang J; Qiu Z
Eur J Med Chem; 2021 Jun; 218():113394. PubMed ID: 33813153
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.
Ge H; Wang C; Tian C; Diao Y; Wang W; Ma X; Zhang J; Li H; Zhao Z; Zhu L
Biomed Pharmacother; 2022 Dec; 156():113884. PubMed ID: 36306591
[TBL] [Abstract][Full Text] [Related]
8. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
F1000Res; 2018; 7():82. PubMed ID: 29399328
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
12. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
[TBL] [Abstract][Full Text] [Related]
14. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
Glück M; Dally L; Jücker M; Ehm P
Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
[TBL] [Abstract][Full Text] [Related]
15. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN
J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors.
Guo Y; Zou Y; Chen Y; Deng D; Zhang Z; Liu K; Tang M; Yang T; Fu S; Zhang C; Si W; Ma Z; Zhang S; Peng B; Xu D; Chen L
Bioorg Chem; 2023 Mar; 132():106386. PubMed ID: 36702002
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2
Hu M; Yang T; Yang L; Niu L; Zhu J; Zhao A; Shi M; Yuan X; Tang M; Yang J; Pei H; Yang Z; Chen Q; Ye H; Niu T; Chen L
Blood Cancer J; 2022 Mar; 12(3):37. PubMed ID: 35256594
[TBL] [Abstract][Full Text] [Related]
19. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
Quintás-Cardama A
Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]